EUROFINS BIOPHARMA PRODUCT TESTING POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Copy
CopyKey data
Status
KRS number
CopyREGON
CopyNIP/VAT code
CopyVAT registration date
VAT status
Bankruptcy proceedings
EUROFINS BIOPHARMA PRODUCT TESTING POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Contacts
Registered address
Copy
Website
-
B
HighReliability
B - HighIncorporation date
30/05/2022Share capital
5,000.00 PLNPrimary activity
Other technical testing and analysis (71.20.B - PKD 2007)Representatives
1Representatives rights
W PRZYPADKU ZARZĄDU JENOOSOBOWEGO LUB WIELOOSOBOWEGO DO SKŁADANIA OŚWIADCZEŃ WOLI W IMIENIU SPÓŁKI UPRAWNIONY JEST KAŻDY CZŁONEK ZARZĄDU DZIAŁAJĄCY SAMODZIELNIE.Representatives
Business linkages
Premium users: 1.00 credit
Financial report (Okredo)
Premium users: 1.00 credit
People
Representatives
Person  | Title |
|---|---|
G**** G***** | Chairman of the management board |
Persons with Significant Control
Persons with Significant Control
This information is available in our reports and to subscription users.Financial ratios
Net Profit (zł)
436,322Net Profit (zł)
436,322Financial report (Okredo)
Premium users: 1.00 credit
| Indicator |
|---|
| Turnover (zł) |
| Profit before tax (zł) |
| Net Profit (zł) |
Working capital requirement (%) The working capital requirement indicator shows how much funds a company needs to develop and maintain a business. |
| Liquidity ratioliquidityRatio |
| Net profitability (%)This ratio is commonly referred to as a company’s “bottom line” and is a true indicator of a company’s profitability. It shows how much a net profit of € 1 (or other monetary unit) is generated by sales. |
| Equity (zł) |
| Current liabilities (zł) |
| Non current liabilities (zł) |
| Non-current Assets (zł) |
| 2022 |
|---|
| 111,678 |
| -31,313 |
| -31,313 |
| -0.06 |
| 0.91 |
| -28.04 |
| -26,313 |
| 73,527 |
| 0 |
| 3,339 |
| 2023 |
|---|
| 1,565,202 |
| -25,906 |
| -20,758 |
| -0.02 |
| 0.95 |
| -1.33 |
| -47,071 |
| 640,662 |
| 0 |
| 39,040 |
| 2024 |
|---|
| 3,807,747 |
| 479,255 |
| 436,322 |
| 0.12 |
| 1.82 |
| 11.46 |
| 389,252 |
| 540,076 |
| 20,227 |
| - |
| 2024 |
|---|
| 3,807,747 |
| 479,255 |
| 436,322 |
| 0.12 |
| 1.82 |
| 11.46 |
| 389,252 |
| 540,076 |
| 20,227 |
| - |
Turnover (zł)
2024
Turnover (zł)
3,807,747 zł
143 % *
Profit before tax (zł)
479,255 zł1,950 % *
Net Profit (zł)
436,322 zł2,202 % *
Working capital requirement (%)
0.12 
700.00 % *
Liquidity ratio
1.82 91.58 % *
Net profitability (%)
11.46 %961.65 % *
Equity (zł)
389,252 zł927 % *
Current liabilities (zł)
540,076 zł
-16 % *
Non current liabilities (zł)
20,227 zł
- *
Non-current Assets (zł)
-Credit history
No. of unpaid debts
0
Largest debt
-
Amount of unpaid debts
€0.00
Oldest open debt
-
No. of unpaid debts
0
Largest debt
-
Amount of unpaid debts
€0.00
Oldest open debt
-
Credit report
Creditor/Data source | Debt amount | Debt date | Debt type |
|---|---|---|---|
- | - | - | - |
Creditor/Data source | Debt amount | Debt date | Payment date | Debt type |
|---|---|---|---|---|
- | - | - | - | - |
Documents
EUROFINS BIOPHARMA PRODUCT TESTING POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ Documents
Date | Description |
|---|---|
27/05/2025 | OD 01.01.2024 DO 31.12.2024 |
07/08/2024 | OD 01.01.2023 DO 31.12.2023 |
30/06/2023 | OD 14.01.2022 DO 31.12.2022 |